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Abstract: Fetal alcohol spectrum disorders (FASD) are the physical and neurodevelopmental 
outcomes of fetal alcohol exposure. The behavioral phenotype of children with FASD includes 
difficulties with executive function, memory, planning, processing speed, and attention. Although 
attention deficit hyperactivity disorder (ADHD) is diagnosed in up to 94% of individuals with 
heavy prenatal alcohol exposure, the exact relationship between FASD and ADHD is unclear. 
There is some evidence that ADHD in FASD may be a specific clinical subtype and thus may 
require a different treatment approach. Although traditional behavioral observation scales may 
not distinguish between the two groups, there is evidence that children with FASD have a dif-
ferent profile on the four-factor model of attention than children with ADHD who do not have 
FASD. There is a paucity of good scientific evidence on effective interventions for individuals 
with ADHD and FASD. There is weak evidence that children with FASD and ADHD may have 
a better response to dexamphetamine than methylphenidate. There is a strong need for larger, 
high quality studies to examine the relationship between ADHD and FASD and identify effec-
tive treatments because management of inattention and hyperactivity may improve learning and 
ameliorate the common secondary disabilities associated with FASD.
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Introduction
Disruptive, hyperactive, and impulsive behaviors are highly prevalent in individuals 
with fetal alcohol spectrum disorders (FASD).1 In this paper we discuss the relation-
ship between attention deficit hyperactivity disorder (ADHD) and FASD. Firstly, we 
define ADHD and FASD and review the epidemiology of these conditions. Then we 
discuss the rationale for distinguishing between ADHD with and without FASD and 
review the evidence regarding the relationship between ADHD and FASD. Finally, 
we discuss the approach to diagnosis and management of ADHD in individuals with 
FASD.
Attention deficit hyperactivity disorder
ADHD may be thought of as a group of conditions with similar behavioral   symptoms 
consequent to different etiologies.2 ADHD is defined as a persistent pattern of   behavior 
including hyperactivity and impulsivity, and/or inattention that is more severe and 
frequent than is usually seen in an individual at the same stage of development. 
The Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) 
defines three subtypes, ie, a combined type which includes symptoms of inattention and 
hyperactivity or impulsivity, a predominantly inattentive type, in which   hyperactive Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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and impulsive symptoms are minor, and a predominantly 
hyperactive-impulsive type, in which inattentive symptoms 
are minor.3 The subtypes may be discontinued in DSM-5.4 
The mean intelligence quotient (IQ) score and IQ distribution 
in the ADHD population are similar to that in the general 
population.2,5 ADHD is a neurobiologic disorder with genetic 
and environmental origins. Family, adoption, and twin 
  studies demonstrate a strong genetic contribution to ADHD, 
which involves polymorphisms in a number of genes, such as 
those which code for dopamine transporters. Environmental 
risk factors for ADHD include antenatal exposure to toxins, 
such as alcohol and tobacco, prematurity, adverse childhood 
experiences, childhood illness, head trauma, and exposure 
to environmental toxins.3 The heterogeneity of ADHD may 
be explained partially by the varying contribution of genes 
and environmental factors for individual children. ADHD is 
reported in all ethnic groups and social classes. The preva-
lence of ADHD in children in the general population ranges 
from 5% to 11%.3,6
Fetal alcohol spectrum disorders
Fetal alcohol syndrome (FAS) was first described in 
1973,7 but descriptions of the effects of alcohol exposure 
  during pregnancy date back to ancient history.8 FASD is 
a   nondiagnostic umbrella term for the possible childhood 
outcomes of prenatal alcohol exposure. FASD includes FAS, 
partial FAS, alcohol-related neurodevelopmental disorder 
(ARND), and alcohol-related birth defects. Individuals with 
FAS have specific facial features (including short palpebral 
fissures, flat philtrum, and thin upper lip), impaired prenatal 
and/or postnatal growth, and structural or functional prob-
lems of the central nervous system. If all of these features 
are present and differential diagnoses are excluded, the diag-
nosis of FAS can be made even if alcohol exposure during 
pregnancy is not confirmed. Individuals with partial FAS 
have most, but not all, the features of FAS. Individuals with 
ARND have a complex pattern of behavioral and/or neuro-
logic impairment without the physical features of FAS. Fetal 
alcohol effects (FAE) is an obsolete term previously used to 
describe individuals with incomplete features of FAS. The 
facial features of FAS occur with fetal alcohol exposure early 
in the first trimester, but neuropsychologic deficits may occur 
independent of the physical features of FAS.9 In FAS, IQ 
scores are reported to range from 20 to 120 with an average 
IQ score between 68 and 72. Individuals with ARND have a 
slightly higher IQ than individuals with FAS.2 Internationally, 
several diagnostic approaches to FASD have been proposed. 
Although the diagnostic criteria and terminology used differ 
only slightly, the use of different approaches is confusing and 
makes comparison of study results difficult.10–13 The estimated 
prevalence of FAS is 0.5–2.0 per 1000 births, although a 
prevalence of up to 68 per 1000 has been reported in some 
high-risk communities.14,15 The prevalence of the other FASD 
diagnoses is not well defined, but it is estimated that FASD 
affects 1% of all births in the US.14
Many studies have focused on defining the behavioral 
phenotype of FASD to assist diagnosis and intervention. 
Individuals with FASD frequently display deficits in execu-
tive functioning, memory, attention, visual-spatial abilities, 
planning, cognitive flexibility, processing speed, inhibition 
and inhibition/switching, deductive reasoning and verbal 
abstract thinking, problem solving, verbal and spatial concept 
formation, phonemic switching and phonologic working 
memory, and motor skills.16,17 Executive function deficits are 
present in individuals with FASD whether or not they have 
FAS.18,19 Older children with FASD are more impaired than 
younger children on verbal processing tasks.17 These deficits 
may contribute to lower IQ scores, poor academic achieve-
ment, and learning problems.17 Long-term studies show that 
adolescents and young adults with FASD have high rates 
of secondary disabilities including mental health problems 
(90%), inappropriate sexual behavior (49%), disrupted school 
education (60%), and trouble with the law (60%). More than 
one third experience drug and alcohol problems.20 These 
secondary disabilities may arise from the neurobehavioral 
deficits caused by prenatal alcohol exposure, with exacerba-
tion or amelioration by environmental factors.9
Attention and hyperactivity 
problems in FASD
Children with FASD are often described as hyperactive, dis-
tractible, and impulsive, with short attention spans.21 ADHD 
is the most commonly reported mental health diagnosis in 
individuals with prenatal alcohol exposure.1,22 The prevalence 
of ADHD (diagnosed according to DSM-IV criteria) in chil-
dren with heavy prenatal alcohol exposure is between 49.4% 
and 94%.1,22 Unfortunately, prevalence studies have included 
children with heavy prenatal alcohol exposure (variously 
defined), with and without a diagnosis of FASD, hence the 
wide prevalence range. However, the prevalence of ADHD in 
cohorts with FASD is consistently much higher than that in the 
general population. The proportion of children with a diagnosis 
of ADHD who also have FASD is not known and will be influ-
enced by underdiagnosis of FASD. Underdiagnosis occurs due 
to a variety of factors, including health professionals’ reluc-
tance to ask about alcohol exposure in pregnancy or to make Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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a diagnosis due to lack of knowledge or fear of stigmatizing 
the child.23–25 The proportion of children with FAS diagnosed 
with ADHD increases with the level of alcohol exposure.1 
Attention deficit in individuals with FASD is independent of 
IQ and persists into adolescence and adulthood.22,26,27 Inatten-
tion symptoms are more commonly reported in children with 
FASD who meet DSM-IV criteria for ADHD, than in children 
with ADHD who do not have FASD.28
Rationale for distinguishing between 
ADHD and FASD
The prognosis and treatment responses for children with 
ADHD and FASD differ to those of children with ADHD 
alone. Children with FASD often present with early onset 
ADHD with predominant inattentive symptoms.6 They are 
at high risk of secondary disabilities, which can be amelio-
rated by early diagnosis of FASD and management of its 
symptoms, especially if diagnosis is before the age of six 
years. The reason for the improved prognosis is unclear 
because there are few specific interventions for children 
with FASD, but it may relate to improved understanding and 
appropriate expectations of the children by their caregivers 
and teachers.20
Individuals with FASD may respond differently to 
  stimulant medication than other children with ADHD. 
  Specifically, children with FASD appear to have a   differential 
response to methylphenidate and dexamphetamine. In a 
case series of 30 children with FASD and ADHD, 22% 
(of 23 children) responded to methylphenidate, while 79% 
(of 19 children) responded to dexamphetamine. Of the 
children given both medications, eight did not respond to 
  methylphenidate but later responded to dexamphetamine, one 
child did not respond to dexamphetamine but later responded 
to methylphenidate, and three children did not respond 
to either medication.29 The apparently increased response 
rate to dexamphetamine may be explained by animal work 
  showing that rats who were prenatally exposed to alcohol and 
had physical hyperactivity showed “hyperresponsiveness” 
to methylphenidate and that alcohol exposure acts on the 
D1 dopamine receptors of the mesolimbic system, which is 
the site of action of dexamphetamine.6,30,31 Decreased effec-
tiveness of   methylphenidate in animal and human studies 
suggests that the front nigrostriatal pathway may not be the 
mechanism in patients with FASD and comorbid ADHD.6
ADHD and FASD
There may be multiple pathways to the coexistence of 
ADHD symptoms and FASD, so there may be different 
subsets of ADHD and FASD.6,32 The relationship between 
ADHD and FASD may be coincidental because ADHD is 
a common disorder affecting up to 11% of children in the 
general population. Adults with ADHD are more likely to 
drink alcohol, thus pregnant women with ADHD who drink 
alcohol during pregnancy may genetically transmit ADHD 
to their offspring.6
There may be common etiological pathways to ADHD and 
the behavioral phenotype of FASD. Alternatively, acquired 
ADHD secondary to prenatal alcohol exposure may be due to 
the effect of alcohol on the developing dopamine   transmitter 
system. These two hypotheses are supported by changes in the 
neurochemistry seen in animal studies of fetal alcohol   exposure 
in which deficits have been found in most   neurotransmitter 
systems, including the dopaminergic,   noradrenergic, 
  serotonergic, cholinergic, glutaminergic, gamma aminobutyric 
acid (GABA)-ergic, and   histaminergic systems. Deficits in 
noradrenergic and dopaminergic   systems are the most likely 
ones to be related to the ADHD   symptoms seen in animals with 
prenatal alcohol exposure. The D1   receptors of the mesolimbic 
dopamine system tend to be affected by alcohol exposure more 
than other dopamine systems.6
Some studies support the idea that ADHD in FASD is a 
particular clinical subtype with earlier onset, a different clini-
cal and neuropsychologic profile, and a different response 
to psychostimulant medications. The Seattle Longitudinal 
Prospective Study suggests that infants with a history of 
prenatal alcohol exposure have an infant regulatory disorder 
and temperament disturbance which precede the diagnosis 
of ADHD. Research has shown that animals with prenatal 
alcohol exposure have an exaggerated response to psycho-
stimulants, which is mediated by age, gender, and drug 
dosage. There is evidence suggesting that individuals with 
FASD and ADHD have a better response to dexamphetamine 
than methylphenidate. Patients, such as those with FASD, 
who have neurochemical or structural changes in the central 
nervous system are often hypersensitive to the effects and 
side effects of medication, and psychostimulant response in 
these patients may improve with age.6
Adaptive behavior
Adaptive function is the ability to meet developmentally 
appropriate expectations of personal independence and social 
responsibility, including performance of everyday tasks, and 
adapt to changes in the environment.33 Adaptive behavior 
is affected in both FASD and ADHD. Using the Vinelands 
Adaptive Behavior Scale, three groups were compared, ie, 
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ADHD, and normally developing children. Children with 
prenatal alcohol exposure and children with ADHD had 
significantly lower scores on the communication domain than 
controls and, in the prenatal alcohol exposure group, age was 
negatively associated with score. Children in the prenatal 
alcohol exposure and ADHD groups had significantly lower 
scores on daily living skills, but the prenatal alcohol exposure 
group had significantly lower scores than the ADHD group. 
Children in the prenatal alcohol exposure and ADHD groups 
had significantly lower scores on socialization, but did not 
differ from each other. Again, age was negatively associ-
ated with the scores in the prenatal alcohol exposure group. 
Within the FASD group, children scored best in daily living 
skills and scored worst on socialization and communication 
domains. They demonstrated increasing adaptive behavior 
deficits with age. The children with ADHD had difficulty 
with socialization skills and their adaptive behavior skills 
improved with age. Overall, children in the prenatal alcohol 
exposure group were more likely than children in the ADHD 
and control groups to be rated as having inadequate adap-
tive skills. When analyzed with matched IQs, the prenatal 
alcohol exposure and ADHD groups did not differ from each 
other. For adaptive behavior skills, the differences between 
children with prenatal alcohol exposure and children with 
ADHD may be accounted for by IQ.33
Executive function
Executive function is the higher order process involved 
in thought and action under conscious control, usually to 
achieve a goal. It involves planning, inhibition, working 
memory, organized speech, set-shifting, strategy employ-
ment, flexible thinking, and fluency.17 Executive function 
is probably mediated by the frontal cortex, and prenatal 
alcohol exposure may affect frontal cortex development.17 
Neuropsychologic measures of executive function assess 
organization, planning, working memory, inhibition of inap-
propriate responses, and set-shifting.2
The common symptoms of behavioral disinhibition and 
attention deficit in FASD and ADHD may be related to 
problems with executive function.2 There is evidence that 
executive function is a core deficit in FASD and ADHD, 
and neuroimaging shows that children with FASD and 
ADHD may have structural and functional abnormalities in 
the frontal-subcortical circuits, which are areas associated 
with executive function. Behavioral data also confirm that 
both populations have deficits in global adaptive abilities. 
There is conflicting evidence regarding executive function 
deficits in ADHD.2
Nanson et al21 conducted a prospective cohort study com-
paring children with FAS or FAE with normal developing 
(control) children and children with attention deficit disorder 
(ADD) without FAS or FAE. Behavioral characteristics were 
similar between the FAS/FAE and ADD groups. There were 
no differences on parental rating for the two groups, suggest-
ing it is difficult to distinguish between the two groups using 
traditional observational scales. The FAS/FAE group tended 
to have slower performance and was more likely to improve 
with practice than the ADD group. Unlike the ADD group, 
the FAS/FAE group was not able to trade off accuracy in 
favor of increased speed.21
Coles et al34 compared children with prenatal alco-
hol   exposure, children with ADHD without prenatal 
alcohol exposure, and control children with neither prenatal 
alcohol exposure nor ADHD. They used traditional   behavioral 
and psychiatric measures of ADHD and externalizing 
  behavior and neurocognitive measures of a four-factor model 
of attention. Children with FAS or FAE had similar global 
intellectual deficits to children with ADHD. Both groups 
had difficulty with sequential functioning, but the FAS/FAE 
group had greater difficulties on visual-spatial reasoning. The 
FAS/FAE group struggled on arithmetic, while ADHD group 
were poorer on reading/decoding. The FAS/FAE group had 
nonsignificant decreases in scores on reading/decoding. Both 
the FAS/FAE and ADHD groups had trouble with coding in 
the revised edition of the Wechsler Intelligence Scale for 
Children. The FAS/FAE children had problems with encoding 
on the second list of the paired-associate task and the number 
of categories completed on the Wisconsin Card Sorting Test 
(WCST). On behavioral measures, the ADHD group scored 
highest on the Child Behavior Checklist, the SNAP and the 
DISC (diagnostic interview schedule for children) interview 
items but the FAS/FAE group only differed from the control 
group on the attention score on the Child Behavior Check-
list. On the Computer Performance Task, the ADHD group 
had poor speed and accuracy, slower reaction times, and 
more false alarms (associated with impulsivity). They also 
had fewer hits and more misses. However, there was a large 
dropout of children from the Computer Performance Task 
(60% of the ADHD group, 52% of the FAS/FAE group, and 
43% of controls). Using the four-factor model of attention, 
the FAS/FAE group had problems with encoding and shift, 
while the ADHD group had difficulties with focus and sustain. 
The results of this study suggested that children with ADHD 
and FAS/FAE have unique attentional profiles, and thus the 
neurocognitive deficits may not be the same. The authors 
recommend that children with ADHD are best identified using Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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behavior checklists and measures of the ability to focus and 
sustain attention, while children with FAS/FAE have deficits 
in visual-spatial skills, encoding of information, and flex-
ibility in problem solving.34
Vaurio et al2 examined executive function in children 
with heavy prenatal alcohol exposure, children with ADHD 
who were not exposed to prenatal alcohol, and children with 
neither ADHD nor prenatal alcohol exposure. The children 
with prenatal alcohol exposure performed worse than the 
ADHD group on letter fluency and category fluency. On Trail 
making Test-B, the prenatal alcohol exposure group differed 
significantly from the control group. The ADHD group did 
not differ significantly from the control group on this test. 
The prenatal alcohol exposure and ADHD groups had similar 
deficits on the WCST and both performed more poorly on 
letter fluency than category fluency. However, letter fluency 
was significantly poorer in the prenatal alcohol exposure 
group. In this study the prenatal alcohol exposure group 
performed better on the WCST than predicted by IQ but the 
ADHD group performed more poorly than predicted by IQ. 
This finding for the prenatal alcohol exposure group was in 
conflict with previous studies in which executive function 
deficits remained or worsened when IQ was controlled.2
Summary
In summary, there is some evidence for distinguishing 
between children with FASD and children with ADHD. 
Using the four-factor model of attention it has been shown 
that children with FASD have difficulties with encoding and 
shift, while the children with ADHD have problems with 
focus and sustain. Other findings have not been consistently 
reproduced across studies and the usefulness of traditional 
behavioral observation scales for distinguishing between 
the two groups has not been proven. The main obstacles to 
comparison of study findings are the use of different inclu-
sion criteria, definitions and outcome measures. In particular, 
published studies frequently include children with heavy 
prenatal alcohol exposure (variously defined) with or without 
confirmed FASD in one group.
Diagnosis of the impulsive, 
hyperactive, or inattentive child
The diagnosis of ADHD should only be made after a compre-
hensive assessment including a medical, developmental and 
psychosocial history, and examination. The DSM-IV criteria 
are the minimum requirement for a diagnosis of ADHD.3 
ADHD is not an etiologic diagnosis, and assessment of the 
impulsive, hyperactive, or inattentive child should always 
include a thorough history and examination for potential 
causes, including alcohol exposure in pregnancy. Although 
enquiry regarding alcohol exposure in pregnancy should be 
routine, many health professionals do not ask.24,25
Behavioral rating scales can provide useful information, 
in a standardized format, from multiple informants, and can 
be used to monitor response to treatment. Many measures are 
available, such as the Child Behavior Checklist, the Strength 
and Difficulties Questionnaires, and specific ADHD scales, 
eg, the Conners’ rating scales. The Behavior Rating Inventory 
of Executive Function (BRIEF) is a useful tool for evaluat-
ing behavioral, social, and emotional aspects of executive 
functioning in children with FASD.35
Standard criteria should be used for the diagnosis of 
FASD.10–13 The choice of diagnostic criteria will be deter-
mined by local guidelines and clinician preference. Assess-
ment and diagnosis of FASD usually requires input from 
medical and allied health professionals due to the range 
of physical and neurologic structural and functional issues 
which can occur in FASD and are required to fulfill diag-
nostic criteria.
Treatment of ADHD in FASD
There is a paucity of high quality evidence assessing inter-
ventions for children with both FASD and ADHD.36 There 
are two very small, randomized, controlled trials which 
examine the use of stimulant medication. The first study 
compared methylphenidate with placebo (n = 4). Compared 
with placebo, methylphenidate improved hyperactivity and 
impulsivity symptoms but not attention.37 Adverse effects 
from the methylphenidate were reported for three of the four 
children, and one child had to discontinue methylphenidate 12 
weeks into the trial due to excessive weight loss. In the second 
study, usual stimulant medication was compared with pla-
cebo (n = 12). Compared with placebo, stimulants improved 
hyperactivity symptoms but not attention.38 Psychopharma-
cologic agents have also been examined in retrospective and 
uncontrolled studies.29,39,40 In one study, stimulant medication 
improved hyperactivity and impulsivity scores, but inatten-
tion was less responsive to medication.40 In a retrospective 
study, there was a suggestion that children with ADHD and 
FASD had a preferential response to dexamphetamine.29 The 
role of atomoxetine is being assessed in two studies including 
one randomized controlled trial.36
There is one study of behavioral or psychological inter-
vention for children with FASD and ADHD symptoms, in 
which 23 children were randomized to receive attention 
process training or contact control sessions.36 The group Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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receiving attention process training had significantly more 
improvement on measures of sustained attention and non-
verbal reasoning ability than controls, but not on measures 
of executive function.
Because there is little evidence specific to the manage-
ment of ADHD in FASD, the approach to intervention is 
mostly extrapolated from the ADHD literature. Multimodal 
therapy is the recommended treatment for ADHD in all age 
groups. This could include pharmacologic and behavioral 
interventions. The Multi-modal Treatment Study of Chil-
dren with Attention-Deficit/Hyperactivity Disorder demon-
strated that pharmacologic management was superior to an 
intensive behavioral intervention at a 14-months follow-up. 
  Compared with pharmacologic management alone, combined 
  pharmacologic and intensive behavioral interventions did 
not significantly improve core ADHD symptoms, but treat-
ment outcomes were achieved with a significantly lower 
dose of medication in the combined treatment group than in 
the pharmacologic management group.41 The management 
plan should also take into consideration the comorbidities 
of ADHD and FASD.3,6
Medication will not be needed for all individuals with 
ADHD and should only be used when the symptoms 
are pervasive across settings and are causing significant 
impairment in academic, social, or behavioral domains. 
Individuals receiving medication require regular review, at 
least six monthly. Medications for ADHD include stimulant 
(methylphenidate and dexamphetamine) and nonstimulant 
medications (eg, atomoxetine). Stimulant medications are 
thought to act by altering the availability of dopamine and 
noradrenaline, which influences behavior inhibition, impulse 
control, and attention.3 Clinicians should consider trialing 
dexamphetamine first, because there is some evidence sug-
gesting that children with FASD have a preferential response 
to dexamphetamine over methylphenidate. Methylphenidate 
is available in immediate-release and extended-release 
formulations, but there is no evidence regarding the use of 
extended-release methylphenidate preparations in children 
with FASD. Atomoxetine is a nonstimulant medication 
which is classified as a noradrenaline reuptake inhibitor.3 
The evidence regarding atomoxetine use in FASD is pend-
ing. There is no evidence available regarding the use of other 
nonstimulant medications in FASD.
Conclusion
ADHD is the most frequent comorbidity of FASD but the 
exact relationship between the two entities is not well defined. 
There is some evidence that a specific clinical subtype of 
ADHD occurs in FASD, with earlier onset and a different 
response to medication. However, the relationship between 
ADHD and FASD may be coincidental, may reflect a com-
mon etiologic pathway, or may reflect the frequent genetic 
origin of ADHD and its prevalence in the general population. 
It is likely that a range of these etiologic factors account for 
ADHD in FASD, resulting in a heterogeneous population, 
which makes it difficult to replicate or generalize findings 
across studies.
Impairment of executive function may be a common 
underlying factor in ADHD and FASD but, using the four-
factor model of attention, there is evidence of difference 
between these two groups. Children with FASD have dif-
ficulties with encoding and shift, and children with ADHD 
without FASD have problems with focus and sustain. If this 
difference is reproducible in large cohorts, then it may be 
useful for diagnosis in the clinical population.
There are clinical benefits to clarifying whether an 
individual has FASD because early diagnosis of FASD can 
ameliorate the secondary disabilities. There may be a dif-
ferential medication response in individuals with ADHD 
who also have FASD, in particular a possible preferential 
response to dexamphetamine. However, the evidence to 
support treatments for ADHD in FASD is scarce.
There is a need for large, high quality studies examining 
the etiology, diagnosis, and interventions for ADHD in FASD 
because there is the potential to modify significantly the poor 
adult outcomes associated with the secondary disabilities. 
Agreement on the most appropriate diagnostic criteria and 
terminology for FASD and standardization of outcome mea-
sures would improve the translation of research findings into 
clinical practice. The development of effective interventions 
will be guided by improved understanding of the etiology 
of ADHD in FASD and the ability to diagnose FASD more 
accurately.
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